Qiagen delivered a solid second-quarter performance, driven by rising demand for its diagnostic solutions and improved profitability. The company exceeded both its revenue and earnings expectations and also raised its full-year sales forecast, signaling continued momentum across its core business lines.
Net sales for the quarter rose 7 percent year-over-year to $534 million, or 6 percent at constant exchange rates. This result beat the company’s previous guidance for at least 5 percent CER growth, reflecting strong performance in both diagnostics and life sciences. The growth was led by a significant 11 percent jump in revenue from diagnostic solutions, which included standout gains of 41 percent in QIAstat-Dx sales and 11 percent in QuantiFERON. Qiagen also saw healthy contributions from companion diagnostics, reinforcing its position in personalized healthcare.
Adjusted diluted earnings per share came in at $0.60, exceeding internal targets and showing the benefit of margin expansion and cost efficiency. The company’s adjusted operating income margin improved to 29.9 percent, up by 1.5 percentage points compared to the same period last year. This improvement reflects disciplined spending and a favorable mix of high-margin product lines.
Given the strength of the second quarter, Qiagen raised its full-year constant currency sales growth outlook to a range of 4 to 5 percent, up slightly from its previous expectation of around 4 percent. The company maintained its adjusted EPS guidance of approximately $2.35 at CER, suggesting stable profitability for the rest of the year.
The strong Q2 results and optimistic guidance show that Qiagen is effectively navigating macroeconomic challenges and capturing growth in high-demand segments of the diagnostics market. Continued innovation in molecular testing and steady demand for tools like QIAstat-Dx and QuantiFERON are expected to keep driving results in the coming quarters.